|
[1]
|
Cao, M., Li, H., Sun, D., et al. (2020) Cancer Burden of Major Cancers in China: A Need for Sustainable Actions. Can-cer Communications (London), 40, 205-210. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Zhou, J., Zheng, R., Zhang, S., et al. (2022) Gastric and Esophageal Cancer in China 2000 to 2030: Recent Trends and Short-Term Predictions of the Future Burden. Cancer Medicine, 11, 1902-1912. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
中华医学会肿瘤学分会, 中华医学会杂志社. 中华医学会胃癌临床诊疗指南(2021版) [J]. 中华医学杂志, 2022, 102(16): 1169-1189.
|
|
[4]
|
赫捷, 陈万青, 李兆申, 等. 中国胃癌筛查与早诊早治指南(2022, 北京) [J]. 中华肿瘤杂志, 2022, 44(7): 634-666.
|
|
[5]
|
Schmitz, J., Owyang, A., Oldham, E., et al. (2005) IL-33, an Interleukin-1-Like Cytokine That Signals via the IL-1 Receptor-Related Protein ST2 and Induces T Helper Type 2-Associated Cytokines. Immunity, 23, 479-490. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Jiang, W., Lian, J., Yue, Y., et al. (2021) IL-33/ST2 as a Poten-tial Target for Tumor Immunotherapy. European Journal of Immunology, 51, 1943-1955. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Angulo, E.L., Mckernan, E.M., Fichtinger, P.S., et al. (2019) Compar-ison of IL-33 and IL-5 Family Mediated Activation of Human Eosinophils. PLOS ONE, 14, e0217807. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Cayrol, C. and Girard, J.P. (2014) IL-33: An Alarmin Cytokine with Crucial Roles in Innate Immunity, Inflammation and Allergy. Current Opinion in Immunology, 31, 31-37. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Fang, M., Li, Y., Huang, K., et al. (2017) IL33 Promotes Colon Cancer Cell Stemness via JNK Activation and Macrophage Recruitment. Cancer Research, 77, 2735-2745. [Google Scholar] [CrossRef]
|
|
[10]
|
Zhou, Q., Wu, X., Wang, X., et al. (2020) The Reciprocal Interaction between Tumor Cells and Activated Fibroblasts Mediated by TNF-α/IL-33/ST2L Signaling Promotes Gastric Cancer Metastasis. Oncogene, 39, 1414-1428. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Tong, X., Barbour, M., Hou, K., et al. (2016) Interleukin-33 Pre-dicts Poor Prognosis and Promotes Ovarian Cancer Cell Growth and Metastasis through Regulating ERK and JNK Sig-naling Pathways. Molecular Oncology, 10, 113-125. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
O'donnell, C., Mahmoud, A., Keane, J., et al. (2016) An Anti-tumorigenic Role for the IL-33 Receptor, ST2L, in Colon Cancer. British Journal of Cancer, 114, 37-43. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Ye, X.L., Zhao, Y.R., Weng, G.B., et al. (2015) IL-33-Induced JNK Pathway Activation Confers Gastric Cancer Chemotherapy Resistance. Oncology Reports, 33, 2746-2752. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Yu, X.X., Hu, Z., Shen, X., et al. (2015) IL-33 Promotes Gastric Cancer Cell Invasion and Migration via ST2-ERK1/2 Pathway. Digestive Diseases and Sciences, 60, 1265-1272. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Huang, N., Cui, X., Li, W., et al. (2021) IL-33/ST2 Promotes the Malignant Progression of Gastric Cancer via the MAPK Pathway. Molecular Medicine Reports, 23, Article No. 361. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Cayrol, C. and Girard, J.P. (2018) Interleukin-33 (IL-33): A Nuclear Cytokine from the IL-1 Family. Immunological Reviews, 281, 154-168. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Taniguchi, S., Elhance, A., Van Duzer, A., et al. (2021) Response to Com-ment on “Tumor-Initiating Cells Establish an IL-33-TGF-β Niche Signaling Loop to Promote Cancer Progression”. Sci-ence, 372, eabf3316. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Kakkar, R., Hei, H., Dobner, S., et al. (2012) Interleukin 33 as a Me-chanically Responsive Cytokine Secreted by Living Cells. Journal of Biological Chemistry, 287, 6941-6948. [Google Scholar] [CrossRef]
|
|
[19]
|
Uchida, A.M., Lenehan, P.J., Vimalathas, P., et al. (2022) Tissue Eosinophils Express the IL-33 Receptor ST2 and Type 2 Cytokines in Patients with Eosinophilic Esophagitis. Allergy, 77, 656-660. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Rasheed, K., Moens, U., Policastro, B., Johnsen, J.I., et al. (2022) The Merkel Cell Polyomavirus T-Antigens and IL-33/ST2-IL1RAcP Axis: Possible Role in Merkel Cell Carcinoma. In-ternational Journal of Molecular Sciences, 23, 3702. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Lefrançais, E., Roga, S., Gautier, V., et al. (2012) IL-33 Is Processed into Mature Bioactive Forms by Neutrophil Elastase and Cathep-sin G. Proceedings of the National Academy of Sciences of the United States of America, 109, 1673-1678. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Lefrançais, E., Duval, A., Mirey, E., et al. (2014) Central Domain of IL-33 Is Cleaved by Mast Cell Proteases for Potent Activation of Group-2 Innate Lymphoid Cells. Proceedings of the National Academy of Sciences of the United States of America, 111, 15502-15507. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Eissmann, M.F., Buchert, M. and Ernst, M. (2020) IL33 and Mast Cells—The Key Regulators of Immune Responses in Gastrointestinal Cancers? Frontiers in Immunology, 11, 1389. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
杨敬端, 何明, 吴品. 炎症因子IL-33通过mTOR/Akt信号通路调节肥大细胞反应抑制萎缩性胃炎[J]. 免疫学杂志, 2022, 38(4): 324-331.
|
|
[25]
|
Eissmann, M.F., Dijkstra, C., Jarnicki, A., et al. (2019) IL-33-Mediated Mast Cell Activation Promotes Gastric Cancer through Macrophage Mobiliza-tion. Nature Communications, 10, 2735. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Faas, M., Ipseiz, N., Ackermann, J., et al. (2021) IL-33-Induced Metabolic Reprogramming Controls the Differentiation of Alternatively Ac-tivated Macrophages and the Resolution of Inflammation. Immunity, 54, 2531-2546.e5. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Aasarød, K.M., Mosti, M.P., Stunes, A.K., et al. (2016) Im-paired Skeletal Health in Patients with Chronic Atrophic Gastritis. Scandinavian Journal of Gastroenterology, 51, 774-781. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Petersen, C.P., Meyer, A.R., De Salvo, C., et al. (2018) A Signalling Cascade of IL-33 to IL-13 Regulates Metaplasia in the Mouse Stomach. Gut, 67, 805-817. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
De Salvo, C., Pastorelli, L., Petersen, C.P., et al. (2021) Interleu-kin 33 Triggers Early Eosinophil-Dependent Events Leading to Metaplasia in a Chronic Model of Gastritis-Prone Mice. Gastroenterology, 160, 302-316.e7. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Andreone, S., Gambardella, A.R., Mancini, J., et al. (2020) An-ti-Tumorigenic Activities of IL-33: A Mechanistic Insight. Frontiers in Immunology, 11, Article ID: 571593. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Minton, K. (2019) Enhancing Antitumour Eosinophils. Nature Reviews Immunology, 19, 202-203. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
汤洁莹, 李薇薇, 杨建民. IL-33/ILC2通路在组织损伤修复及纤维化中的作用机制研究进展[J]. 中华整形外科杂志, 2022, 38(8): 951-955.
|
|
[33]
|
Jacquelot, N., Seillet, C., Wang, M., Pizzolla, A., et al. (2021) Blockade of the Co-Inhibitory Molecule PD-1 Unleashes ILC2-Dependent Antitumor Im-munity in Melanoma. Nature Immunology, 22, 851-864. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Wagner, M., Ealey, K.N., Tetsu, H., et al. (2020) Tumor-Derived Lactic Acid Contributes to the Paucity of Intratumoral ILC2s. Cell Reports, 30, 2743-2757.e5. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Moral, J.A., Leung, J., Rojas, L.A., et al. (2020) ILC2s Amplify PD-1 Blockade by Activating Tissue-Specific Cancer Immunity. Nature, 579, 130-135. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Pisani, L.F., Tontini, G.E., Gentile, C., et al. (2021) Proinflam-matory Interleukin-33 Induces Dichotomic Effects on Cell Proliferation in Normal Gastric Epithelium and Gastric Cancer. International Journal of Molecular Sciences, 22, 5792. [Google Scholar] [CrossRef]
|
|
[37]
|
Gonciarz, W., Krupa, A., Moran, A.P., et al. (2021) Inter-ference of LPS H. pylori with IL-33-Driven Regeneration of Caviae porcellus Primary Gastric Epithelial Cells and Fi-broblasts. Cells, 10, 1385. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Chen, L., Sun, R., Xu, J., et al. (2020) Tumor-Derived IL33 Promotes Tissue-Resident CD8(+) T Cells and Is Required for Checkpoint Blockade Tumor Immunotherapy. Cancer Immunology Research, 8, 1381-1392. [Google Scholar] [CrossRef]
|
|
[39]
|
Kim, Y., Ma, C., Park, S., et al. (2021) Rational Design, Synthesis and Evaluation of Oxazolo[4,5-c]-quinolinone Analogs as Novel Interleukin-33 Inhibitors. Chemistry—An Asian Journal, 16, 3702-3712. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Hu, W., Li, X., Li, Q., et al. (2017) Interleukin-33 Expression Does Not Correlate with Survival of Gastric Cancer Patients. Pathology and Oncology Research, 23, 615-619. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Taniguchi, S., Elhance, A., Van Duzer, A., et al. (2020) Tu-mor-Initiating Cells Establish an IL-33-TGF-β Niche Signaling Loop to Promote Cancer Progression. Science, 369, eaay1813. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Jovanovic, M.Z., Geller, D.A., Gajovic, N.M., et al. (2022) Dual Blockage of PD-L/PD-1 and IL33/ST2 Axes Slows Tumor Growth and Improves Antitumor Immunity by Boost-ing NK Cells. Life Sciences, 289, Article ID: 120214. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Mizuno, S., Matsui, D., Watanabe, I., et al. (2015) Serologically Determined Gastric Mucosal Condition Is a Predictive Factor for Osteoporosis in Japanese Men. Digestive Diseases and Sciences, 60, 2063-2069. [Google Scholar] [CrossRef] [PubMed]
|